Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 28 articles: HTML format

Single Articles

April 2025
1. KU BS, Hamilton H, Yuan Q, Parker DA, et al
   Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons.
   Neuropsychopharmacology. 2025 Apr 2. doi: 10.1038/s41386-025-02093.
   PubMed     Abstract available
   
   
   March 2025
2. DHAMALA E, Rubio JM
   Persistent brain network signatures in psychosis: implications for diagnosis, prognosis, and treatment.
   Neuropsychopharmacology. 2025 Mar 5. doi: 10.1038/s41386-025-02079.
   PubMed    
   
   
   February 2025
3. DYBOWSKI FP, Scott DS, Tamminga CA
   Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
   Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02077.
   PubMed     Abstract available
   
   
   
4. FOSTER ML, Ye J, Powers AR, Dvornek NC, et al
   Connectome-based predictive modeling of early and chronic psychosis symptoms.
   Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02064.
   PubMed     Abstract available
   
   
   
5. SAMSOM JN, Xu M, Avila A, Daskalakis AA, et al
   Protein interacting with C-kinase 1 (PICK1) regulates synaptic function and reversal learning in a mouse model for schizophrenia.
   Neuropsychopharmacology. 2025 Feb 22. doi: 10.1038/s41386-025-02072.
   PubMed     Abstract available
   
   
   November 2024
6. ZHANG W, Wang L, Wu X, Yao L, et al
   Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia.
   Neuropsychopharmacology. 2024 Nov 6. doi: 10.1038/s41386-024-02021.
   PubMed     Abstract available
   
   
   September 2024
7. BRAKATSELOS C, Polissidis A, Ntoulas G, Asprogerakas MZ, et al
   Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
   Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01977.
   PubMed     Abstract available
   
   
   August 2024
8. SLIFSTEIN M, Qu W, Gil R, Weinstein JJ, et al
   Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.
   Neuropsychopharmacology. 2024 Aug 31. doi: 10.1038/s41386-024-01975.
   PubMed     Abstract available
   
   
   July 2024
9. ABRAM SV, Hua JPY
   Pons connectivity correlates with neurophysiological and clinical signatures of predictive coding in psychosis.
   Neuropsychopharmacology. 2024 Jul 22. doi: 10.1038/s41386-024-01919.
   PubMed    
   
   
   
10. SMUCNY J, Carter CS
    Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy.
    Neuropsychopharmacology. 2024 Jul 18. doi: 10.1038/s41386-024-01932.
    PubMed    
    
    
    June 2024
11. JOHNSON EC, Austin-Zimmerman I, Thorpe HHA, Levey DF, et al
    Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 21. doi: 10.1038/s41386-024-01886.
    PubMed     Abstract available
    
    
    
12. CHENOWETH MJ
    Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 11. doi: 10.1038/s41386-024-01898.
    PubMed    
    
    
    
13. KOCH E, Kampe A, Alver M, Siguretharson S, et al
    Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study.
    Neuropsychopharmacology. 2024;49:1113-1119.
    PubMed     Abstract available
    
    
    May 2024
14. PISANU C, Congiu D, Meloni A, Paribello P, et al
    Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.
    Neuropsychopharmacology. 2024;49:1033-1041.
    PubMed     Abstract available
    
    
    April 2024
15. LIVINGSTON NR, Kiemes A, Devenyi GA, Knight S, et al
    Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2024 Apr 24. doi: 10.1038/s41386-024-01864.
    PubMed     Abstract available
    
    
    March 2024
16. SCHOONOVER KE, Dienel SJ, Holly Bazmi H, Enwright JF 3rd, et al
    Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia.
    Neuropsychopharmacology. 2024 Mar 28. doi: 10.1038/s41386-024-01854.
    PubMed     Abstract available
    
    
    
17. HUANG AS, Kang K, Vandekar S, Rogers BP, et al
    Lifespan development of thalamic nuclei and characterizing thalamic nuclei abnormalities in schizophrenia using normative modeling.
    Neuropsychopharmacology. 2024 Mar 13. doi: 10.1038/s41386-024-01837.
    PubMed     Abstract available
    
    
    
18. SEITZ-HOLLAND J, Aleman-Gomez Y, Cho KIK, Pasternak O, et al
    Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
    Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814.
    PubMed     Abstract available
    
    
    February 2024
19. CABRERA-MENDOZA B, Aydin N, Fries GR, Docherty AR, et al
    Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach.
    Neuropsychopharmacology. 2024 Feb 23. doi: 10.1038/s41386-024-01833.
    PubMed     Abstract available
    
    
    
20. TRUONG TTT, Liu ZSJ, Panizzutti B, Kim JH, et al
    Network-based drug repurposing for schizophrenia.
    Neuropsychopharmacology. 2024 Feb 6. doi: 10.1038/s41386-024-01805.
    PubMed     Abstract available
    
    
    January 2024
21. PAUL SM, Potter WZ
    Finding new and better treatments for psychiatric disorders.
    Neuropsychopharmacology. 2024;49:3-9.
    PubMed     Abstract available
    
    
    
22. HANSON JE, Yuan H, Perszyk RE, Banke TG, et al
    Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
    Neuropsychopharmacology. 2024;49:51-66.
    PubMed     Abstract available
    
    
    December 2023
23. ARIME Y, Saitoh Y, Ishikawa M, Kamiyoshihara C, et al
    Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia.
    Neuropsychopharmacology. 2023 Dec 4. doi: 10.1038/s41386-023-01769.
    PubMed     Abstract available
    
    
    October 2023
24. WANG DM, Chen DC, Xiu MH, Wang L, et al
    A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
    Neuropsychopharmacology. 2023 Oct 30. doi: 10.1038/s41386-023-01760.
    PubMed     Abstract available
    
    
    
25. ROESKE MJ, McHugo M, Rogers B, Armstrong K, et al
    Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Neuropsychopharmacology. 2023 Oct 13. doi: 10.1038/s41386-023-01730.
    PubMed     Abstract available
    
    
    September 2023
26. FAN L, Liang L, Wang Y, Ma X, et al
    Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
    Neuropsychopharmacology. 2023 Sep 26. doi: 10.1038/s41386-023-01741.
    PubMed     Abstract available
    
    
    
27. ZHOU DY, Su X, Wu Y, Yang Y, et al
    Decreased CNNM2 expression in prefrontal cortex affects sensorimotor gating function, cognition, dendritic spine morphogenesis and risk of schizophrenia.
    Neuropsychopharmacology. 2023 Sep 15. doi: 10.1038/s41386-023-01732.
    PubMed     Abstract available
    
    
    
28. RABIN RA, Palaniyappan L
    Brain health in ethnically minority youth at risk for psychosis.
    Neuropsychopharmacology. 2023 Sep 4. doi: 10.1038/s41386-023-01719.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.